| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/03/2009 | US20090220582 Method of cancer treatment using sirna silencing |
| 09/03/2009 | US20090220581 Methods of reducing inflammation and mucus hypersecretion |
| 09/03/2009 | US20090220580 Percutaneous Absorption Formulation |
| 09/03/2009 | US20090220579 Gelatin Non-Woven Structures Produced by a Non-Toxic Dry Solvent Spinning Process |
| 09/03/2009 | US20090220578 Hydrogel composition and method for making the same |
| 09/03/2009 | US20090220577 Moulded body for medically treating wounds |
| 09/03/2009 | US20090220576 Emulsion |
| 09/03/2009 | US20090220575 Compositions and methods for the sustained release of beta-alanine |
| 09/03/2009 | US20090220574 Suramin and derivatives thereof as topical microbicide and contraceptive |
| 09/03/2009 | US20090220573 Method, Device, and System for Delivery of Therapeutic Agents to the Eye |
| 09/03/2009 | US20090220572 Injectable Combination Therapy for Eye Disorders |
| 09/03/2009 | US20090220562 Osteogenic and anti-adipogenic oxysterols |
| 09/03/2009 | US20090220560 Nanosilver Coated Bacterial Cellulose |
| 09/03/2009 | US20090220557 Effect pigment and use thereof in cosmetics and in the food and pharmaceutical industries |
| 09/03/2009 | US20090220554 Transglutaminase Inhibitors and Methods of Use Thereof |
| 09/03/2009 | US20090220553 Composition and Method for Inhibiting, Preventing, or Ameliorating Complications Associated With Ingestion of a Medicinal, Chemical, or Biological Substance or Agent |
| 09/03/2009 | US20090220552 Formulations containing pantoprazole free acid and its salts |
| 09/03/2009 | US20090220436 In situ polymerization for skin treatment |
| 09/03/2009 | US20090220435 Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents |
| 09/03/2009 | US20090220426 Biodegradable Inverted-Opal Structure, Method for Manufacturing and Using the Same, and Medical Implant Comprising the Biodegradable Inverted-Opal Structure |
| 09/03/2009 | US20090220422 Drug Delivery Material |
| 09/03/2009 | US20090218731 Shaped body and method for production of said body |
| 09/03/2009 | US20090218229 Coating process and apparatus with improved resistance to bacteria |
| 09/03/2009 | CA2752444A1 Delivery apparatus and associated method |
| 09/03/2009 | CA2729129A1 Use of black soybean for treating ophthalmic diseases |
| 09/03/2009 | CA2717133A1 Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye |
| 09/03/2009 | CA2716901A1 Process to minimize polymorphism |
| 09/03/2009 | CA2716835A1 Methods of treating cardiovascular disorders associated with atherosclerosis |
| 09/03/2009 | CA2716745A1 Method for producing an implantable bone composition |
| 09/03/2009 | CA2716658A1 Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
| 09/03/2009 | CA2716546A1 Sugar glassified virus like particles (vlps) |
| 09/03/2009 | CA2716466A1 Prophylactic or therapeutic agent for eye disease accompanied by optic nerve disorder |
| 09/03/2009 | CA2716351A1 Sweetened capsules for administration |
| 09/03/2009 | CA2716336A1 Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders |
| 09/03/2009 | CA2715802A1 Pharmaceutical composition for poorly soluble drugs |
| 09/03/2009 | CA2714942A1 Stabilized single-liquid pharmaceutical composition containing docetaxel |
| 09/03/2009 | CA2714502A1 Compositions and methods for augmentation and regeneration of living tissue in a subject |
| 09/03/2009 | CA2714190A1 Tablets and preparation thereof |
| 09/03/2009 | CA2713581A1 Valsartan solid oral dosage forms and methods of making such formulations |
| 09/02/2009 | EP2095825A1 Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
| 09/02/2009 | EP2095817A1 Therapeutic compositions and methods |
| 09/02/2009 | EP2095816A1 Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
| 09/02/2009 | EP2095815A1 Pharmaceutical formulations containing clopidogrel |
| 09/02/2009 | EP2095814A1 Nicotine withdrawal supported by medication |
| 09/02/2009 | EP2095813A1 Tablet for buccal, sublingual or gingival administration, comprising an effervescent couple |
| 09/02/2009 | EP2095812A1 Granular preparation prevented from caking |
| 09/02/2009 | EP2095811A1 Ointment for stopping hair loss, helping it to grow back and for getting rid of age spots and wrinkles, getting rid of phlebitis and varicose veins |
| 09/02/2009 | EP2094771A2 Treated substrates having improved delivery of impregnated ingredients |
| 09/02/2009 | EP2094729A1 Abeta antibody parenteral formulation |
| 09/02/2009 | EP2094348A1 Delivery system for a non-steroidal non-ionized hydrophilic drug |
| 09/02/2009 | EP2094308A1 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
| 09/02/2009 | EP2094281A2 Use of lipid conjugates in the treatment of diseases or disorders of the eye |
| 09/02/2009 | EP2094275A2 Methods and formulations for improved bioavailability of antiprogestins |
| 09/02/2009 | EP2094270A1 Delivery system for risperidone |
| 09/02/2009 | EP2094262A1 Pharmaceutical composition containing phenanthrenequinone-based compound for intestine delivery system |
| 09/02/2009 | EP2094261A1 Pharmaceutical composition containing naphthoquinone-based compound for intestine delivery system |
| 09/02/2009 | EP2094256A1 Method for alleviating keratoconjunctivitis sicca |
| 09/02/2009 | EP2094251A2 Powder formulation for inhalation |
| 09/02/2009 | EP2094250A1 Transdermal therapeutic system comprising ion pair micro-reservoirs |
| 09/02/2009 | EP2094249A2 Transdermal therapeutic system for administering the active substance buprenorphine |
| 09/02/2009 | EP2094248A2 Ibuprofen composition |
| 09/02/2009 | EP2094247A2 Stable polypeptide formulations |
| 09/02/2009 | EP2094246A1 Sustained-release composition and method for producing the same |
| 09/02/2009 | EP2094245A2 Stable powder formulation containing a novel anticholinergic agent |
| 09/02/2009 | EP2094244A2 Spray-freeze-drying process for the preparation of pellets comprising percolation drying |
| 09/02/2009 | EP2094243A2 Anionic latex as a carrier for bioactive ingredients and methods for making and using the same |
| 09/02/2009 | EP2094241A2 Oral formulations |
| 09/02/2009 | EP2094240A2 Stable powder formulation containing an anticholinergic agent |
| 09/02/2009 | EP2094239A1 Liposome preparation by single-pass process |
| 09/02/2009 | EP2094238A2 Improvements in or relating to amphoteric liposomes |
| 09/02/2009 | EP2094237A1 Lipid growth factor formulations |
| 09/02/2009 | EP2094236A1 Gel useful for the delivery of ophthalmic drugs |
| 09/02/2009 | EP2094235A2 Ocular devices and methods of making and using thereof |
| 09/02/2009 | EP2094213A1 Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |
| 09/02/2009 | EP2094106A1 Capsules from separated polymer solutions |
| 09/02/2009 | EP1812032A4 Tissue factor composition and methods |
| 09/02/2009 | EP1765291B1 Enhanced medical product |
| 09/02/2009 | EP1696932B1 Use of treprostinil to improve kidney functions |
| 09/02/2009 | EP1620056B1 Tumor cytotoxicity induced by modulators of the cxcr4 receptor |
| 09/02/2009 | EP1496870B1 Dosage form and method for producing the same |
| 09/02/2009 | EP1478233A4 Method for administering glp-1 molecules |
| 09/02/2009 | EP1411913A4 Antimicrobial nanoemulsion compositions and methods |
| 09/02/2009 | EP1353663B1 Fenofibrate tablets |
| 09/02/2009 | EP1326584B1 Delivery system and method of treating or preventing otitis media |
| 09/02/2009 | EP1317479B1 Methods and compositions for diseases associated with amyloidosis |
| 09/02/2009 | EP1228125A4 Process for making aqueous coated beadlets |
| 09/02/2009 | CN201299813Y Tablet capsule containing aspirin tablet and dipyridamole tablet |
| 09/02/2009 | CN201299812Y Tablet capsule used for treating helicobacter pylori (HP) infection |
| 09/02/2009 | CN101522178A Transdermal therapeutic system comprising ion pair micro-reservoirs |
| 09/02/2009 | CN101522177A Microencapsules containing surface-modified microparticles and methods of forming and using the same |
| 09/02/2009 | CN101522176A Formulations of flibanserin and method for manufacturing the same |
| 09/02/2009 | CN101522175A Solubilized non-steroidal anti-inflammatory drugs |
| 09/02/2009 | CN101522174A Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions |
| 09/02/2009 | CN101522173A Solid composites of a calicum receptor-active compound |
| 09/02/2009 | CN101522172A Cancer treatments |
| 09/02/2009 | CN101522171A Self-preserved aqueous pharmaceutical compositions |
| 09/02/2009 | CN101522170A Subcutaneous implants releasing an active principle over an extended period of time |
| 09/02/2009 | CN101522169A Subcutaneous implants releasing an active principle over an extended period of time |
| 09/02/2009 | CN101522168A Capecitabine pediatric tablets |
| 09/02/2009 | CN101522167A Galenic form for the trans-mucosal delivery of active ingredients |